Anticoagulation

Apixaban Is Safest Direct Oral Anticoagulant vs Warfarin

Apixaban Is Safest Direct Oral Anticoagulant vs Warfarin

Apixaban reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin.

Dabigatran May Reduce Major Vascular Complication Risk After Noncardiac Surgery

Dabigatran May Reduce Major Vascular Complication Risk After Noncardiac Surgery

By

Dabigatran may be associated with a risk reduction of major vascular complications in patients who develop a myocardial injury after noncardiac surgery.

Gastroprotective Effects of PPIs, H2RAs Compared in Patients on Clopidogrel

Gastroprotective Effects of PPIs, H2RAs Compared in Patients on Clopidogrel

By

For this study, researchers searched several large databases (from 1980 to 2016) for randomized, controlled trials (RCTs) that compared clinical outcomes in patients on DAPT taking PPIs or H2RAs.

Troponin-T, NT-proBNP May Predict Mortality Risk in Atrial Fibrillation

Troponin-T, NT-proBNP May Predict Mortality Risk in Atrial Fibrillation

By

Troponin-T, N-terminal pro-B-type natriuretic peptide, and growth differentiation factor-15 may offer prognostic utility on mortality and bleeding events in patients with atrial fibrillation who receive anticoagulation.

Pulmonary Embolism AEs Increase With DOAC Doses Against Manufacturer Recs

Pulmonary Embolism AEs Increase With DOAC Doses Against Manufacturer Recs

By

Patients treated for acute pulmonary embolism with direct oral anticoagulants at doses against manufacturer recommendations had a higher rate of major bleeding events.

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

By

Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.

Perioperative VTE Prophylaxis Assessment in Post-Pubertal Adolescents

Perioperative VTE Prophylaxis Assessment in Post-Pubertal Adolescents

A decision-making algorithm on venous thromboembolism prophylaxis was developed by the Association of Paediatric Anaesthetists of Great Britain and Ireland.

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

By

The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

By

A greater burden of atrial fibrillation or flutter in patients with paroxysmal atrial fibrillation was associated with a higher risk for stroke when not taking anticoagulants.

Reduced-Dose Anticoagulants Feasible for Extended VTE Treatment

Reduced-Dose Anticoagulants Feasible for Extended VTE Treatment

Reduced doses be as effective as full-dose direct oral anticoagulants for extended-duration venous thromboembolism treatment.

Extended INR Test Intervals Safe for Warfarin-Treated Patients

Extended INR Test Intervals Safe for Warfarin-Treated Patients

Similar number of out-of-range next INR values were seen in patients with and without extended testing interval.

First Generic Alternative for Mephyton Now Available

First Generic Alternative for Mephyton Now Available

By

Amneal's generic product is available in a 5mg strength tablet supplied in 100-count bottles.

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

By

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

By

Anxiety may increase the risk for ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation.

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

By

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.

Venous Thromboembolism Prevention After Joint Arthroplasty With Rivaroxaban or Aspirin

Venous Thromboembolism Prevention After Joint Arthroplasty With Rivaroxaban or Aspirin

Extended prophylaxis with aspirin does not differ significantly from rivaroxaban for venous thromboembolism prevention in patients who have undergone total hip or knee arthroplasty.

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

By

Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.

Anticoagulants in Elderly With Afib, CKD May Increase Stroke Risk

Anticoagulants in Elderly With Afib, CKD May Increase Stroke Risk

Anticoagulants are associated with increased risk for ischemic stroke and hemorrhage in older patients with chronic kidney disease and a new diagnosis of atrial fibrillation.

A 45-Year-Old Man Presents to the ED With Shortness of Breath, Confusion

A 45-Year-Old Man Presents to the ED With Shortness of Breath, Confusion

By

A 45-year-old man presents to the emergency department with some mental confusion and near syncope.

Acute Coronary Syndrome Benefits From Both Antiplatelets and DOACs

Acute Coronary Syndrome Benefits From Both Antiplatelets and DOACs

Treatment with direct oral anticoagulants in addition to antiplatelet therapy appears efficacious for patients with STEMI.

A 35-Year-Old Pregnant Woman Presents With Progressive Dyspnea and Palpitations

A 35-Year-Old Pregnant Woman Presents With Progressive Dyspnea and Palpitations

By

A 35-year-old pregnant woman presents to the emergency department with progressive dyspnea and palpitations that have worsened during the last 3 weeks.

Anticoagulation During Cardiopulmonary Bypass: First-Ever Guidelines Released

Anticoagulation During Cardiopulmonary Bypass: First-Ever Guidelines Released

Clinical practice guidelines for anticoagulation therapy for cardiopulmonary bypass have been developed.

Measuring Cost-Effectiveness of DOACs, Warfarin for Stroke Prevention

Measuring Cost-Effectiveness of DOACs, Warfarin for Stroke Prevention

By

Cost-effective DOACs like apixaban prevent strokes better than warfarin in patients with atrial fibrillation.

Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial Fibrillation

Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial Fibrillation

By

In patients with atrial fibrillation at high risk for stroke, edoxaban is associated with lower rates of cardiovascular death events.

Triple Therapy in Coronary Artery Disease With GI Bleeding May Increase Mortality Risk

Triple Therapy in Coronary Artery Disease With GI Bleeding May Increase Mortality Risk

Triple therapy is associated with increased mortality risk in patients with LGIB and CAD.

Renal Function Outcomes in Atrial Fibrillation With Oral Anticoagulation Therapy

Renal Function Outcomes in Atrial Fibrillation With Oral Anticoagulation Therapy

By

Patients with atrial fibrillation who are treated with oral anticoagulants often experience renal function decline.

Warfarin Chemical Stability Not Affected by Repackaging Into Dose Administration Aids

Warfarin Chemical Stability Not Affected by Repackaging Into Dose Administration Aids

The chemical stability of warfarin sodium tablets is not affected by repackaging into dose administration aids.

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

By

A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.

ACC Expert Consensus: Management of Bleeding Associated With Oral Anticoagulants

ACC Expert Consensus: Management of Bleeding Associated With Oral Anticoagulants

By

The American College of Cardiology released an expert consensus decision pathway intended to guide clinicians in managing bleeding in patients treated with anticoagulation.

Incident Atrial Fibrillation: Direct Oral Anticoagulants vs Warfarin

Incident Atrial Fibrillation: Direct Oral Anticoagulants vs Warfarin

By

Compared with warfarin, direct oral anticoagulants lowered the risk for stroke and death risk in patients with incident atrial fibrillation.

Sign Up for Free e-Newsletters